- Home
- AVNW vs MNPR Comparison
AVNW vs MNPR Comparison
Compare AVNW & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVNW
- MNPR
- Stock Information
- Founded
- AVNW 2006
- MNPR 2014
- Country
- AVNW United States
- MNPR United States
- Employees
- AVNW N/A
- MNPR N/A
- Industry
- AVNW Radio And Television Broadcasting And Communications Equipment
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- AVNW Technology
- MNPR Health Care
- Exchange
- AVNW Nasdaq
- MNPR Nasdaq
- Market Cap
- AVNW 214.0M
- MNPR 249.5M
- IPO Year
- AVNW 2007
- MNPR 2019
- Fundamental
- Price
- AVNW $20.81
- MNPR $33.82
- Analyst Decision
- AVNW Strong Buy
- MNPR Strong Buy
- Analyst Count
- AVNW 5
- MNPR 5
- Target Price
- AVNW $37.60
- MNPR $59.50
- AVG Volume (30 Days)
- AVNW 97.0K
- MNPR 18.3K
- Earning Date
- AVNW 05-06-2025
- MNPR 05-13-2025
- Dividend Yield
- AVNW N/A
- MNPR N/A
- EPS Growth
- AVNW N/A
- MNPR N/A
- EPS
- AVNW N/A
- MNPR N/A
- Revenue
- AVNW $435,926,000.00
- MNPR N/A
- Revenue This Year
- AVNW $8.97
- MNPR N/A
- Revenue Next Year
- AVNW $6.53
- MNPR N/A
- P/E Ratio
- AVNW N/A
- MNPR N/A
- Revenue Growth
- AVNW 14.58
- MNPR N/A
- 52 Week Low
- AVNW $12.96
- MNPR $1.72
- 52 Week High
- AVNW $32.13
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- AVNW 66.25
- MNPR 40.83
- Support Level
- AVNW $20.18
- MNPR $37.81
- Resistance Level
- AVNW $21.65
- MNPR $44.40
- Average True Range (ATR)
- AVNW 0.89
- MNPR 3.89
- MACD
- AVNW 0.38
- MNPR -1.03
- Stochastic Oscillator
- AVNW 77.73
- MNPR 3.62
About AVNW Aviat Networks Inc.
Aviat Networks Inc is a networking solutions provider. It designs, manufactures and sells wireless networking products, solutions, and services to mobile and fixed operators, private network operators, government agencies, transportation and utility companies, public safety agencies, and broadcast network operators around the world. The company's product categories include point-to-point microwave and millimeter wave radios that are licensed (subject to local frequency regulatory requirements), lightly licensed and license-exempt (operating in license-exempt frequencies), and element and network management software.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.